This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 0.68% and 1,467.86%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
IGM Biosciences, Inc. (IGMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
IGM Biosciences (IGMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Praxis Precision Medicines, Inc. (PRAX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Praxis Precision Medicines (PRAX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ensign Group (ENSG) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 1.36% and 0.81%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines, Inc. (PRAX) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of -36.82% and 42.70%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines (PRAX) Moves 8.4% Higher: Will This Strength Last?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 26.89% and 75.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -148% and 40.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys (FEMY) delivered earnings and revenue surprises of -16.67% and 55.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
by Zacks Equity Research
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -7.81% and 37.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 15.08% and 31.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
Praxis (PRAX) Surges on Positive Epilepsy Study Results
by Zacks Equity Research
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines, Inc. (PRAX) delivered earnings and revenue surprises of 5.71% and 71.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Praxis Precision Medicines, Inc. (PRAX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.